Delivery Order SPE2DB20D2104-SPE2DB25FMXJR
- Not listed
- The U.S. Defense Department's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Linzess 290mg capsules (30-count) with a ceiling value of $1,932.27. This firm fixed-price delivery order is non-competitive and is scheduled for completion by September 4, 2025. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and critical vendor for federal medical procurement, particularly...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Linzess 72 microgram capsules (30-count unit of use packaging) with a ceiling value of $1,155.69. This firm fixed-price delivery order, which is expected to be completed by August 15, 2025, represents a non-competitive set-aside award and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order falls under...
- The Defense Logistics Agency awarded a delivery order valued at $6,017.50 to AmerisourceBergen Drug Corp for the supply of Linzess 145 mcg capsules (30-count units), with an ultimate completion date of September 11, 2025. This competitive, firm fixed-price delivery order was issued on September 10, 2025, with performance directed to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's broader Indefinite...
- The Defense Logistics Agency awarded a delivery order valued at $1,064.49 to AmerisourceBergen Drug Corp for Linzess 290 microgram capsules (30-count units) on August 7, 2025, with an ultimate completion date of August 8, 2025. This firm fixed-price delivery order represents a non-competitive set-aside award and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions...
- The Defense Logistics Agency awarded a delivery order valued at $1,909.80 to AmerisourceBergen Drug Corp for Linzess 72 microgram capsules (30-count units) on September 3, 2025, with an ultimate completion date of September 4, 2025. This competitive award, which carries no set-aside designation, represents a firm fixed-price delivery order for pharmaceutical supply to support federal medical procurement needs. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in...
- The U.S. Defense Logistics Agency (DLA) Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Linzess 290 micrograms capsules (30-count units) with a ceiling value of $25,753.71. This firm fixed-price delivery order was awarded on September 17, 2025, with an ultimate completion date of September 18, 2025, and was not designated as a set-aside contract. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken,...
- The Defense Logistics Agency awarded a $11,335.78 delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of Linzess 290 microgram capsules in quantities of 30 units. This firm fixed-price contract represents a competitively awarded, non-set-aside procurement with a completion date of August 19, 2025. The product will be performed and delivered from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency (DLA) awarded a $3,061.96 delivery order to AmerisourceBergen Drug Corp for LINZESS 145 micrograms capsules (30-count units) on September 9, 2025, with completion targeted for September 10, 2025. This firm fixed price contract represents a non-competitive delivery order under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 and extending through December 2026. The award supports the company's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of Linzess 290 microgram capsules (30-count units) at a ceiling value of $1,548.94. This is a firm fixed price delivery order with no set-aside designation, indicating it was competitively awarded. The order is scheduled for ultimate completion by August 18, 2025, with performance taking place at the vendor's facility in Conshohocken, Pennsylvania. This delivery order falls...
- The Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on July 17, 2025, for the supply of Linzess 290 mg capsules in a 30-count package. This firm fixed-price delivery order, valued at $6,463.34, represents a non-competitive procurement leveraging an existing Indefinite Delivery Contract (IDC). The order is scheduled for completion by August 13, 2025, with fulfillment through AmerisourceBergen's Corporate Office location in Conshohocken,...
- SPE2DB20D2104Indefinite Delivery Contract
- SPE2DB20D2104-SPE2DB25FMXJRDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $1,392.69 to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of Linzess 290 microgram capsules (30-count unit dose). This is a firm fixed price, competitive delivery order with no set-aside designation and an ultimate completion date of August 11, 2025. The order will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026, which serves as a comprehensive global pharmaceutical support vehicle. AmerisourceBergen Drug Corp is a major pharmaceutical distributor and healthcare solutions provider that supplies a broad range of medical products to federal military and veteran healthcare systems through the Defense Logistics Agency. As a prime contractor on the DLA's comprehensive pharmaceutical distribution contract, the company delivers brand-name and generic medications, vaccines, medical devices, and specialized healthcare commodities across multiple therapeutic domains to support military healthcare programs worldwide. Linzess, used to treat irritable bowel syndrome and chronic constipation, represents one of the specialized pharmaceutical products within AmerisourceBergen's extensive federal medical supply portfolio. The DLA Troop Support Medical contract enables the company to serve the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems through a flexible contracting vehicle designed to ensure consistent availability of critical medical commodities.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.4k | 8/8/25 |